" class="no-js "lang="en-US"> Donald Daley - Medtech Alert
Friday, September 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Donald Daley

Donald Daley

About Donald Daley

Currently CEO of Manchester BIOGEL. Don has been in the pharmaceutical and biotech industry for over 30 years holding various positions within RPR which is now Sanofi and a founder of Argenta Discovery (now part of Charles River Laboratories) and Cetromed (now part of NetScientific).

Related Story

Drug Development

 Cell Guidance Systems and Manchester BIOGEL Collaborate to Launch PODS-Peptigels for 3D Cell Culture | Pharmtech Focus

Cell Guidance Systems and Manchester BIOGEL Collaborate to Launch PODS-Peptigels for 3D Cell Culture

April 6 2022

Cell Guidance Systems Ltd, a specialist in the control, manipulation, and monitoring of cells, both in […]